The Seattle Heart Failure Model
Top Cited Papers
Open Access
- 21 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 113 (11) , 1424-1433
- https://doi.org/10.1161/circulationaha.105.584102
Abstract
Background— Heart failure has an annual mortality rate ranging from 5% to 75%. The purpose of the study was to develop and validate a multivariate risk model to predict 1-, 2-, and 3-year survival in heart failure patients with the use of easily obtainable characteristics relating to clinical status, therapy (pharmacological as well as devices), and laboratory parameters. Methods and Results— The Seattle Heart Failure Model was derived in a cohort of 1125 heart failure patients with the use of a multivariate Cox model. For medications and devices not available in the derivation database, hazard ratios were estimated from published literature. The model was prospectively validated in 5 additional cohorts totaling 9942 heart failure patients and 17 307 person-years of follow-up. The accuracy of the model was excellent, with predicted versus actual 1-year survival rates of 73.4% versus 74.3% in the derivation cohort and 90.5% versus 88.5%, 86.5% versus 86.5%, 83.8% versus 83.3%, 90.9% versus 91.0%, and 89.6% versus 86.7% in the 5 validation cohorts. For the lowest score, the 2-year survival was 92.8% compared with 88.7%, 77.8%, 58.1%, 29.5%, and 10.8% for scores of 0, 1, 2, 3, and 4, respectively. The overall receiver operating characteristic area under the curve was 0.729 (95% CI, 0.714 to 0.744). The model also allowed estimation of the benefit of adding medications or devices to an individual patient’s therapeutic regimen. Conclusions— The Seattle Heart Failure Model provides an accurate estimate of 1-, 2-, and 3-year survival with the use of easily obtained clinical, pharmacological, device, and laboratory characteristics.Keywords
This publication has 35 references indexed in Scilit:
- Mortality Reduction by Implantable Cardioverter-Defibrillators in High-Risk Patients With Heart Failure, Ischemic Heart Disease, and New-Onset Ventricular ArrhythmiaJournal of the American College of Cardiology, 2005
- Usefulness of Relative Lymphocyte Count as an Independent Predictor of Death/Urgent Transplant in Heart FailureThe American Journal of Cardiology, 2005
- Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failureThe American Journal of Cardiology, 2005
- Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving β-blockersThe Journal of Heart and Lung Transplantation, 2004
- Usefulness of depression to predict time to combined end point of transplant or death for outpatients with advanced heart failureThe American Journal of Cardiology, 2004
- Statin therapy is associated with lower mortality among patients with severe heart failureThe American Journal of Cardiology, 2004
- Targeted Anticytokine Therapy in Patients With Chronic Heart FailureCirculation, 2004
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity Commentary: Time for a controlled trial?BMJ, 2000
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999